Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice
- PMID: 12496449
- DOI: 10.4049/jimmunol.170.1.604
Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice
Abstract
Myasthenia gravis (MG) is a T cell-dependent, Ab-mediated autoimmune disease. Ab against muscle acetylcholine receptor (AChR) cause the muscular weakness that characterizes MG and its animal model, experimental MG (EMG). EMG is induced in C57BL6 (B6) mice by three injections of Torpedo AChR (TAChR) in adjuvant. B6 mice develop anti-TAChR Ab that cross-react with mouse muscle AChR, but their CD4+ T cells do not cross-react with mouse AChR sequences. Moreover, murine EMG is not self-maintaining as is human MG, and it has limited duration. Several studies suggest that IL-4 has a protecting function in EMG. Here we show that B6 mice genetically deficient in IL-4 (IL-4-/-) develop long-lasting muscle weakness after a single immunization with TAChR. They develop chronic self-reactive Ab, and their CD4+ T cells respond not only to the TAChR and TAChR subunit peptides, but also to several mouse AChR subunit peptides. These results suggest that in B6 mice, regulatory mechanisms that involve IL-4 contribute to preventing the development of a chronic Ab-mediated autoimmune response to the AChR.
Similar articles
-
Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.J Immunol. 2000 May 15;164(10):5236-44. doi: 10.4049/jimmunol.164.10.5236. J Immunol. 2000. PMID: 10799884
-
C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.J Immunol. 2007 Jun 1;178(11):7072-80. doi: 10.4049/jimmunol.178.11.7072. J Immunol. 2007. PMID: 17513756 Free PMC article.
-
Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.J Clin Invest. 1997 Dec 15;100(12):3027-35. doi: 10.1172/JCI119857. J Clin Invest. 1997. PMID: 9399949 Free PMC article.
-
On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.Crit Rev Immunol. 2001;21(1-3):1-27. Crit Rev Immunol. 2001. PMID: 11642597 Review.
-
Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.Crit Rev Immunol. 1997;17(5-6):481-95. Crit Rev Immunol. 1997. PMID: 9419435 Review.
Cited by
-
TSH receptor-adenovirus-induced Graves' hyperthyroidism is attenuated in both interferon-gamma and interleukin-4 knockout mice; implications for the Th1/Th2 paradigm.Clin Exp Immunol. 2004 Dec;138(3):417-22. doi: 10.1111/j.1365-2249.2004.02641.x. Clin Exp Immunol. 2004. PMID: 15544617 Free PMC article.
-
Serum cytokine and chemokine profiles in patients with myasthenia gravis.Clin Exp Immunol. 2014 May;176(2):232-7. doi: 10.1111/cei.12272. Clin Exp Immunol. 2014. PMID: 24666229 Free PMC article.
-
Effect of complement and its regulation on myasthenia gravis pathogenesis.Expert Rev Clin Immunol. 2008 Jan;4(1):43-52. doi: 10.1586/1744666X.4.1.43. Expert Rev Clin Immunol. 2008. PMID: 20477586 Free PMC article.
-
Serum cytokine profiles in patients with myasthenia gravis.Front Neurol. 2025 Jul 3;16:1611673. doi: 10.3389/fneur.2025.1611673. eCollection 2025. Front Neurol. 2025. PMID: 40689326 Free PMC article.
-
Myasthenia gravis: past, present, and future.J Clin Invest. 2006 Nov;116(11):2843-54. doi: 10.1172/JCI29894. J Clin Invest. 2006. PMID: 17080188 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials